EUVIMEDEUVIMED entdecken
Crossref

Initial therapy in patients with pulmonary arterial hypertension and cardiovascular comorbidities

Athénaïs Boucly iD, David Montani iD, Fabrice Bauer, Elise Artaud-Macari, Emmanuel Bergot, Clément Boissin, Ari Chaouat iD, Vincent Cottin iD, Claire Dauphin, Bruno Degano iD, Pascal De Groote, Camille du Roure und 13 weitere

European Respiratory Journal · 2025-05 · 65 (5) · 2400895

DOI: 10.1183/13993003.00895-2024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Respiratory Journal, online erschienen am 30.01.2025. Verfasst von Athénaïs Boucly und 24 weiteren Autor:innen. Beteiligte Einrichtung: INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France. Hauptthemen laut MEDLINE: Pulmonary Arterial Hypertension, Antihypertensive Agents, Hypertension, Pulmonary, Cardiovascular Diseases. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

European guidelines recommend initial monotherapy in pulmonary arterial hypertension patients with cardiovascular comorbidities based on the limited evidence for combination therapy in this growing population.

Methods

A retrospective analysis was conducted on incident pulmonary arterial hypertension patients enrolled in the French Pulmonary Hypertension Registry between 2009 and 2020. Propensity score matching was used to investigate initial dual oral combination therapy versus oral monotherapy in patients with at least one cardiovascular comorbidity ( i.e. hypertension, obesity, diabetes and coronary artery disease).

Results

Of the 1784 patients identified, 1088 had at least one cardiovascular comorbidity, including 20% with three or comorbidities. In the propensity score-matched population (n=708), the majority of patients were female, with idiopathic/heritable/drug-induced pulmonary arterial hypertension at intermediate 1-year mortality risk. At first follow-up, initial dual therapy led to larger improvements in symptoms, exercise capacity, haemodynamic parameters and risk status than initial monotherapy, with no differences in long‑term survival. Treatment discontinuation was observed in 23% of patients initiated on dual therapy and 24% of those initiated on monotherapy.

Conclusions

Initial dual oral combination therapy may be beneficial and well-tolerated in most pulmonary arterial hypertension patients with cardiovascular comorbidities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Arterial HypertensionAntihypertensive AgentsHypertension, PulmonaryCardiovascular DiseasesHumansFemaleMaleRetrospective StudiesMiddle AgedAgedComorbidityRegistriesDrug Therapy, CombinationPropensity ScoreFranceCoronary Artery DiseaseObesityDiabetes MellitusTreatment Outcome

Substanzen

Antihypertensive Agents

Autor:innen und Institutionen

  • INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France.
  • Université Paris-Saclay, Faculté de Médecine, HPPIT, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Le Kremlin-Bicêtre, France.
  • Assistance Publique - Hôpitaux de Paris (AP-HP), Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
  • INSERM U1096, Normandie Université, UNIROUEN, Department of Cardiac Surgery, CHU de Rouen, Rouen, France.
  • Pneumology Department, Rouen University Hospital, Rouen, France.
  • Unicaen, UFR santé, Service de Pneumologie et Oncologie Thoracique, CHU de Caen, Caen, France.

ORCID-Profile: Athénaïs Boucly, David Montani, Ari Chaouat, Vincent Cottin, Bruno Degano, Marc Humbert, Olivier Sitbon, Laurent Savale

Zitieren

APA

Boucly, A., Montani, D., Bauer, F., Artaud-Macari, E., Bergot, E., Boissin, C., Chaouat, A., Cottin, V., Dauphin, C., Degano, B., De Groote, P., du Roure, C., Favrolt, N., Horeau-Langlard, D., Jaïs, X., Jevnikar, M., Lacoste-Palasset, T., Picard, F., Prévôt, G., …, & Savale, L. (2025). Initial therapy in patients with pulmonary arterial hypertension and cardiovascular comorbidities. European Respiratory Journal, 65(5), 2400895. https://doi.org/10.1183/13993003.00895-2024

Vancouver

Boucly A, Montani D, Bauer F, Artaud-Macari E, Bergot E, Boissin C, et al. Initial therapy in patients with pulmonary arterial hypertension and cardiovascular comorbidities. European Respiratory Journal. 2025;65(5):2400895. doi:10.1183/13993003.00895-2024

BibTeX
@article{Boucly2025,
  author = {Boucly, Athénaïs and Montani, David and Bauer, Fabrice and Artaud-Macari, Elise and Bergot, Emmanuel and Boissin, Clément and Chaouat, Ari and Cottin, Vincent and Dauphin, Claire and Degano, Bruno and De Groote, Pascal and du Roure, Camille and Favrolt, Nicolas and Horeau-Langlard, Delphine and Jaïs, Xavier and Jevnikar, Mitja and Lacoste-Palasset, Thomas and Picard, François and Prévôt, Grégoire and Reynaud-Gaubert, Martine and Roche, Anne and Turquier, Ségolène and Humbert, Marc and Sitbon, Olivier and Savale, Laurent},
  title = {Initial therapy in patients with pulmonary arterial hypertension and cardiovascular comorbidities},
  journal = {European Respiratory Journal},
  year = {2025},
  volume = {65},
  number = {5},
  pages = {2400895},
  doi = {10.1183/13993003.00895-2024}
}
Kostenlos starten →